Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

Biotechnology

Healthcare
$27.39 +1.67%

+$1.22 today

Market cap
$4.56B
Beta
0.37
P/E (TTM)
-37.5
EPS (TTM)
-$1.98
52W Low $36.45High $86.74

Volume 3.23M

Average 1.83M

News

For Ionis Pharmaceuticals, Inc., read summarized stories built from several publishers and recent headlines with links to the original coverage.

Legal & Regulatory

Ionis Gains EU Approval for Tryngolza in Severe Hypertriglyceridemia

Ionis Pharmaceuticals said the European Commission approved Tryngolza (olezarsen) for adults with severe hypertriglyceridemia, or sHTG. The approval covers use alongside diet and other lipid-lowering treatments in patients with fasting triglyceride levels of ≥880 mg/dL (≥10 mmol/L).

Ionis announced the decision on 2026-11-17, saying it broadens Tryngolza's availability in Europe. The company said the therapy is the first RNA-targeted medicine cleared in the EU for this adult group, and the only one.

More headlines

Recent coverage that has not been summarized. Links open the publisher's site.